IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

40.15USD-0.78 (-1.91%)Market Closed

Market Summary

USD40.15-0.78

Market Closed

-1.91%

IONS Alerts

2 major insider sales recently.

Losses in recent quarter

IONS Stock Price

View Fullscreen

IONS RSI Chart

IONS Valuation

Market Cap

5.9B

Price/Earnings (Trailing)

-15.23

Price/Sales (Trailing)

7.55

EV/EBITDA

-18.14

Price/Free Cashflow

-17.17

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-46.84%

Return on Equity

-129.76%

Return on Assets

-13.92%

Free Cashflow Yield

-5.82%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

776.6M

Rev. Growth (Yr)

-8.45%

Rev. Growth (Qtr)

-63.18%

IONS Earnings

Earnings (TTM)

-384.8M

Earnings Growth (Yr)

-14.86%

Earnings Growth (Qtr)

-1.4K%

Breaking Down IONS Revenue

Last 7 days

-6.6%

Last 30 days

-4.9%

Last 90 days

-19.7%

Trailing 12 Months

12.5%

How does IONS drawdown profile look like?

IONS Financial Health

Current Ratio

7.37

Debt/Equity

2.11

Debt/Cashflow

-0.52

IONS Investor Care

Shares Dilution (1Y)

2.01%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	776.6M	0	0	0
2023	576.0M	630.6M	615.0M	787.6M
2022	840.8M	848.8M	875.5M	587.4M
2021	707.5M	687.7M	660.7M	810.5M
2020	958.8M	940.5M	932.7M	729.3M
2019	752.5M	798.5M	821.0M	1.1B
2018	547.3M	552.8M	579.9M	599.7M
2017	425.5M	499.3M	506.7M	518.7M
2016	258.0M	176.0M	237.8M	346.6M
2015	248.6M	257.4M	274.9M	283.7M
2014	132.1M	151.1M	171.5M	214.2M
2013	122.2M	112.9M	124.9M	147.3M
2012	101.2M	123.7M	114.6M	102.0M
2011	99.7M	101.0M	93.1M	99.1M
2010	120.0M	112.5M	114.3M	108.5M
2009	0	112.0M	116.8M	121.6M
2008	0	0	0	107.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ionis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	klein joseph iii	sold	-256,277	42.7128	-6,000	-
Apr 16, 2024	birchler brian	sold	-37,698	41.6555	-905	evp, corp and development ops
Apr 16, 2024	baroldi joseph	sold	-166,641	41.5978	-4,006	evp, chief business officer
Apr 15, 2024	baroldi joseph	acquired	-	-	10,838	evp, chief business officer
Apr 15, 2024	birchler brian	acquired	-	-	1,875	evp, corp and development ops
Feb 29, 2024	swayze eric	acquired	20,827	34.425	605	officer level 14
Feb 29, 2024	geary richard s	acquired	20,792	34.425	604	officer level 14
Feb 29, 2024	bennett c frank	acquired	13,184	34.425	383	officer level 14
Feb 29, 2024	birchler brian	acquired	20,792	34.425	604	vice president level 14
Feb 29, 2024	monia brett p	acquired	18,520	34.425	538	ceo level 15

Which funds bought or sold IONS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	26.00	424,000	5,753,000	0.01%
May 07, 2024	M&T Bank Corp	added	12.72	-9,301	253,699	-%
May 07, 2024	Susquehanna Portfolio Strategies, LLC	reduced	-22.8	-2,905,770	5,678,240	0.13%
May 07, 2024	ASSETMARK, INC	reduced	-85.71	-311	43.00	-%
May 07, 2024	Cornerstone Planning Group LLC	reduced	-58.72	-3,625	1,889	-%
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	1,975,630	1,975,630	0.09%
May 07, 2024	Arizona State Retirement System	reduced	-1.59	-285,864	1,538,360	0.01%
May 07, 2024	AllSquare Wealth Management LLC	unchanged	-	-1,434	8,583	-%
May 07, 2024	Swiss National Bank	added	0.24	-1,815,120	11,049,900	0.01%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	156	3,289,710	6,028,290	-%

Are Funds Buying or Selling IONS?

Are funds buying IONS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IONS

No. of Funds

Unveiling Ionis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.2%	13,201,453	SC 13G
Feb 13, 2024	bb biotech ag	6.0%	8,590,000	SC 13G/A
Feb 13, 2024	vanguard group inc	9.90%	14,203,481	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.3%	9,057,282	SC 13G/A
Jun 09, 2023	vanguard group inc	10.07%	14,414,917	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	8.2%	11,678,259	SC 13G
Feb 14, 2023	bb biotech ag	6.8%	9,635,000	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.54%	13,546,694	SC 13G/A

Recent SEC filings of Ionis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 03, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Ionis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Ionis Pharmaceuticals Inc News

Latest updates

Ionis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-63.2%	119,497,000	324,505,000	144,207,000	188,411,000	130,524,000	151,889,500	159,767,000	133,791,000	141,919,000	440,006,000	133,093,000	125,750,000	111,607,000	290,281,000	160,079,000	145,537,000	133,367,000	493,680,500	167,892,000	163,813,000	297,214,000
Costs and Expenses	-18.6%	269,010,000	330,627,000	287,472,000	278,606,000	244,672,000	359,909,000	218,921,000	219,305,000	199,423,000	219,403,000	218,942,000	198,719,000	203,578,000	312,945,000	196,616,000	197,291,000	194,494,000	233,028,000	165,369,000	182,640,000	175,679,000
S&GA Expenses	-25.9%	52,644,000	71,010,500	69,951,000	46,142,000	45,516,000	47,950,000	34,416,000	33,802,000	34,127,000	37,600,000	31,093,000	56,455,000	61,199,000	138,866,500	68,447,000	72,015,000	74,994,000	83,276,000	60,036,000	75,111,000	68,221,000
EBITDA Margin	-10.3%	-0.44	-0.39	-0.58	-0.41	-0.50	-0.40	0.04	0.00	0.02	-0.01	-0.37	-0.28	-	-	-	-	-	-	-	-	-
Interest Expenses	-8.9%	4,151,000	4,558,000	4,203,000	2,291,000	1,608,000	1,731,000	2,139,000	2,130,000	2,122,000	2,238,000	2,340,000	2,357,000	2,414,000	2,434,000	2,428,000	2,441,000	2,207,000	-22,963,500	12,002,000	11,802,000	11,599,000
Income Taxes	-98.5%	100,000	6,518,500	6,600,000	7,800,000	11,380,000	8,110,000	300,000	2,260,000	1,094,000	334,000	-1,300,000	300,000	130,000	341,114,500	5,064,000	2,084,000	-3,072,000	42,314,500	-14,915,000	-6,900,000	31,000,000
Earnings Before Taxes	-5059.2%	-142,728,000	-2,766,500	-140,808,000	-77,448,000	-112,943,000	-44,330,000	-46,709,000	-102,875,000	-64,071,000	224,914,000	-83,773,000	-80,548,000	-89,739,000	-14,572,500	-31,550,000	-35,476,000	-52,954,000	230,257,500	3,517,000	-16,939,000	121,931,000
EBT Margin	-10.5%	-0.47	-0.42	-0.61	-0.45	-0.53	-0.44	0.01	-0.03	0.00	-0.04	-0.41	-0.31	-	-	-	-	-	-	-	-	-
Net Income	-1441.6%	-142,803,000	-9,263,000	-147,410,000	-85,290,000	-124,323,000	-52,430,000	-46,992,000	-105,135,000	-65,165,000	224,613,000	-82,466,000	-80,875,000	-89,869,000	-85,987,000	-24,467,000	-25,636,000	-39,628,000	184,415,000	26,163,000	-876,000	84,443,000
Net Income Margin	-6.5%	-0.50	-0.47	-0.67	-0.49	-0.57	-0.46	0.01	-0.03	0.00	-0.04	-0.51	-0.46	-	-	-	-	-	-	-	-	-
Free Cashflow	-558.5%	-154,431,000	33,684,000	-111,163,000	-109,375,000	-144,464,000	-204,334,000	-29,971,000	-21,431,000	-34,355,000	201,185,000	-58,897,000	-67,010,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.6%	2,764	2,990	2,934	2,971	2,885	2,534	2,422	2,456	2,519	2,612	2,415	2,497	2,249	2,390	3,096	3,079	3,091	3,233	2,895	2,878	2,836
Current Assets	-8.6%	2,416	2,642	2,585	2,617	2,543	2,203	2,152	2,191	2,253	2,345	2,156	2,238	1,989	2,131	2,537	2,531	2,558	2,721	2,408	2,414	2,374
Cash Equivalents	-12.6%	349	399	352	425	309	276	315	522	543	869	633	565	414	398	633	530	486	683	248	273	376
Inventory	6.5%	30.00	28.00	26.00	26.00	22.00	22.00	21.00	20.00	24.00	25.00	23.00	24.00	22.00	22.00	22.00	24.00	23.00	18.00	19.00	19.00	11.00
Net PPE	2.5%	73.00	71.00	71.00	92.00	85.00	74.00	181	177	178	178	180	179	180	181	182	173	164	154	149	135	134
Liabilities	-5.2%	2,467	2,603	2,619	2,543	2,399	1,961	1,828	1,831	1,810	1,840	1,884	1,914	1,568	1,646	1,489	1,484	1,521	1,549	1,397	1,421	1,448
Current Liabilities	-26.9%	328	448	404	288	259	312	283	268	228	241	280	294	295	599	245	231	258	273	232	241	252
Long Term Debt	-100.0%	-	625	44.00	114	545	-	544	621	543	619	618	617	541	540	450	284	280	435	596	587	577
LT Debt, Current	0.1%	44.00	44.00	-	-	-	-	-	-	-	-	62.00	62.00	62.00	309	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	625	44.00	114	545	-	544	621	543	619	618	617	541	540	450	284	280	435	596	587	577
Shareholder's Equity	-23.3%	297	387	315	428	487	573	594	625	710	772	531	583	681	743	1,521	1,503	1,472	1,577	1,498	1,457	1,387
Retained Earnings	-8.0%	-1,938	-1,795	-1,786	-1,639	-1,553	-1,429	-1,377	-1,330	-1,225	-1,159	-1,384	-1,302	-1,221	-1,131	-909	-878	-846	-707	-857	-883	-882
Additional Paid-In Capital	2.5%	2,270	2,215	2,148	2,118	2,089	2,060	2,035	2,009	1,983	1,964	1,942	1,910	1,926	1,896	2,312	2,272	2,234	2,204	2,219	2,177	2,118
Shares Outstanding	1.0%	146	144	143	143	143	142	142	142	142	141	141	141	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223	218	210	213	162	188	180
Float	-	-	-	-	4,243	-	-	-	3,805	-	-	-	4,675	-	-	-	6,748	-	-	-	7,483	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-556.2%	-149,938	32,865	-109,022	-97,364	-133,992	-200,195	-24,429	-18,096	-31,650	203,687	-55,574	-62,652	-54,662	97,977	-10,275	-44,218	-7,592	277,839	-12,806	-27,111	107,705
Share Based Compensation	19.0%	31,340	26,336	25,963	26,562	26,948	25,689	23,837	24,502	26,236	22,259	30,537	30,021	37,861	95,040	45,844	48,443	40,790	35,010	24,127	41,932	45,505
Cashflow From Investing	384.9%	76,105	-26,713	68,711	69,515	-325,640	212,147	-183,930	-3,304	-287,549	95,109	121,971	-101,030	78,856	187,849	101,940	79,695	-95,007	138,191	1,396	-110,687	-70,174
Cashflow From Financing	-42.1%	23,570	40,724	-32,267	143,538	492,087	-51,019	1,834	1,215	-7,325	-62,490	1,458	314,542	-7,577	-521,480	10,937	8,435	-94,501	19,225	-13,174	34,510	59,460
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.00	90,500	34,400	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IONS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 119,497	$ 130,524
Expenses:
Cost of sales	2,151	1,343
Research, development and patent	214,215	197,813
Selling, general and administrative	52,644	45,516
Total operating expenses	269,010	244,672
Loss from operations	(149,513)	(114,148)
Other income (expense):
Investment income	26,285	18,627
Interest expense	(4,151)	(1,608)
Interest expense related to sale of future royalties	(17,959)	(15,515)
Gain (loss) on investments	2,333	(529)
Other income	277	230
Loss before income tax expense	(142,728)	(112,943)
Income tax expense	(75)	(11,380)
Net loss	$ (142,803)	$ (124,323)
Basic net loss per share (in dollars per share)	$ (0.98)	$ (0.87)
Diluted net loss per share (in dollars per share)	$ (0.98)	$ (0.87)
Shares used in computing basic net loss per share (in shares)	145,538	142,735
Shares used in computing diluted net loss per share (in shares)	145,538	142,735
Commercial Revenue [Member]
Revenue:
Revenue	$ 59,593	$ 67,768
SPINRAZA Royalties [Member]
Revenue:
Revenue	38,455	50,247
WAINUA Royalties [Member]
Revenue:
Revenue	1,125	0
Other Commercial Revenue [Member]
Revenue:
Revenue	20,013	17,521
Research and Development Revenue [Member]
Revenue:
Revenue	59,904	62,756
Collaborative Agreement Revenue [Member]
Revenue:
Revenue	49,345	38,334
WAINUA Joint Development Revenue [Member]
Revenue:
Revenue	$ 10,559	$ 24,422

IONS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 348,889	$ 399,266
Short-term investments	1,857,327	1,931,935
Contracts receivable	5,140	97,778
Inventories	30,259	28,425
Other current assets	174,060	184,449
Total current assets	2,415,675	2,641,853
Property, plant and equipment, net	72,795	71,043
Right-of-use assets	169,431	171,896
Deposits and other assets	106,027	105,280
Total assets	2,763,928	2,990,072
Current liabilities:
Accounts payable	13,082	26,027
Accrued compensation	21,537	67,727
Accrued liabilities	106,048	147,894
Income taxes payable	2,210	2,151
0.125 percent convertible senior notes, net	44,377	44,332
Current portion of deferred contract revenue	130,406	151,128
Other current liabilities	9,988	8,831
Total current liabilities	327,648	448,090
Long-term deferred contract revenue	215,088	241,184
Liability related to sale of future royalties, net	525,072	513,736
Long-term lease liabilities	168,674	170,875
Long-term obligations	41,800	41,836
Total liabilities	2,467,413	2,603,386
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 145,844,719 and 144,340,526 shares issued and outstanding at March 31, 2024 (unaudited) and December 31, 2023, respectively	146	144
Additional paid-in capital	2,270,047	2,215,098
Accumulated other comprehensive loss	(34,964)	(32,645)
Accumulated deficit	(1,938,714)	(1,795,911)
Total stockholders' equity	296,515	386,686
Total liabilities and stockholders' equity	2,763,928	2,990,072
1.75 Percent Convertible Senior Notes [Member]
Current liabilities:
Convertible senior notes, net	562,964	562,285
0 Percent Convertible Senior Notes [Member]
Current liabilities:
Convertible senior notes, net	$ 626,167	$ 625,380

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

CEO	Dr. Brett P. Monia Ph.D.
WEBSITE	ionispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	796

Ionis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ionis Pharmaceuticals Inc? What does IONS stand for in stocks?

IONS is the stock ticker symbol of Ionis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ionis Pharmaceuticals Inc (IONS)?

As of Wed May 08 2024, market cap of Ionis Pharmaceuticals Inc is 5.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers. The fair value of Ionis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ionis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IONS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ionis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IONS is over valued or under valued. Whether Ionis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ionis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IONS.

What is Ionis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, IONS's PE ratio (Price to Earnings) is -15.23 and Price to Sales (PS) ratio is 7.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IONS PE ratio will change depending on the future growth rate expectations of investors.